Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:37AM EDT. Market open.
| Previous close | 23.74 |
| Open | 23.84 |
| Bid | 23.96 x 100 |
| Ask | 24.15 x 100 |
| Day's range | 23.29 - 24.07 |
| 52-week range | 19.65 - 78.47 |
| Volume | |
| Avg. volume | 606,929 |
| Market cap | 1.293B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.76 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.77 |
Business WireProthena to Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024--Prothena announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
ZacksEarnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
© 2024 Yahoo. All rights reserved.